13F Holdings
中文EN

QUCY Quantum Cyber N.V.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1874252 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-0.2%
TTM net income YoY18.0%
TTM EPS YoY66.2%
Revenue 3-yr CAGR15.7%
Net income 3-yr CAGR—

Margins

Gross margin64.3%
Operating margin-2,099.9%
Net margin-2,416.0%
FCF margin-1,950.2%
EBITDA margin-2,022.0%

Returns

ROE-462.0%
ROA-149.4%
ROIC (approx.)—
Asset turnover0.06x

Leverage & solvency

Liabilities / assets55.6%
Debt / equity0.00x
Current ratio1.30x
Interest coverage-19.85x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue11.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$537,080$893,991$895,479$529,877$577,348
Cost of revenue$147,288$319,108$385,820$347,726$399,726
Gross profit$389,792$574,883$509,659$182,151$177,622
R&D expense$4.91M$5.72M$9.59M$5.02M$481,934
SG&A expense$5.11M$6.65M$11.41M$15.21M$8.46M
Operating income-$16.14M-$18.77M-$26.64M-$26.44M-$9.72M
Interest expense$373,458$945,545$522,400$242,020$339,171
Pretax income-$16.21M-$21.60M-$26.30M-$26.39M-$11.69M
Net income-$16.21M-$21.60M-$26.34M-$26.39M-$11.69M
EBITDA-$15.52M-$18.08M-$25.78M-$26.06M-$9.65M
EPS (basic)-2.70-21.91-64.76-74.55-1.62
EPS (diluted)-2.70-21.91-64.76-74.55-1.62
Weighted avg. shares (diluted)6.00M985,717—14.16M7.21M
Banking
Net interest income—-$39,817-$152,562-$65,389—
Balance sheet
Cash & equivalents$701,602$6.24M$7.07M$17.14M$8.73M
Receivables—$33,577$93,555$0$111,842
Inventory$216,888$372,870$613,638$175,469—
Current assets$4.21M$8.02M$8.98M$18.38M$9.61M
PP&E, net$1.09M$1.37M$1.70M$661,692$37,884
Intangibles$1.11M$3.02M$3.39M—$1.20M
Total assets$5.33M$13.50M$15.41M$20.24M$10.04M
Current liabilities$4.69M$6.18M$9.24M$4.24M$1.35M
Short-term debt$956,902$1.02M—$959,116$22,754
Total liabilities$4.69M$7.50M$12.16M$6.14M$3.68M
Shareholders' equity$641,600$6.00M$3.35M$14.10M$6.36M
Shares outstanding9.78M2.32M———
Cash flow statement
Operating cash flow-$10.98M-$17.33M-$21.94M-$14.77M-$3.22M
Capital expenditure$1,216$104,949$1.20M$658,483$16,705
Free cash flow-$10.98M-$17.43M-$23.14M-$15.43M-$3.24M
Investing cash flow-$1.03M-$198,817-$1.90M-$658,483$1.20M
Financing cash flow$6.76M$16.79M$14.23M$23.94M$10.61M
Depreciation & amortization$615,720$696,629$866,412$379,798$69,929
Stock-based compensation$1.47M-$63,117$4.01M$9.82M$6.43M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.